EpiVax Inc - Strategic SWOT Analysis Review

June 2021 | 35 pages | ID: E2A49373C68EN
GlobalData

Abstracts

EpiVax Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T cells. It is an immune-modulation power tool which is being developed for auto-immune, auto-inflammatory and allergic conditions. EpiVax’ service portfolio includes, immune engineering, immunogenicity screening, vaccine design and redesign. It also provides lab services such as in vivo, in vitro and ex vivo immunogenicity screening services including cell-free HLA binding assays. EpiVax is headquartered in Providence, Rhode Island, the US.

EpiVax Inc Key Recent Developments

Dec 29,2020: EpiVax advances 'PANDA' peptide therapeutic immunogenicity screening program
Dec 15,2020: EpiVax reports record year for immunogenicity screening toolkit (ISPRI)
Oct 22,2020: FDA awards $1.1M contract to CUBRC and EpiVax for validation of new immunoinformatic tool for prospective immunogenicity assessment of peptide drugs and their impurities
Jun 03,2020: Intravacc and EpiVax to develop Covid-19 vaccine candidate
Apr 13,2020: Immunomic partners EpiVax and PharmaJet on Covid-19 vaccine

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

EpiVax Inc - Key Facts
EpiVax Inc - Key Employees
EpiVax Inc - Key Employee Biographies
EpiVax Inc - Key Operational Employees
EpiVax Inc - Major Products and Services
EpiVax Inc - History
EpiVax Inc - Company Statement
EpiVax Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
EpiVax Inc - Business Description
EpiVax Inc - SWOT Analysis
SWOT Analysis - Overview
EpiVax Inc - Strengths
EpiVax Inc - Weaknesses
EpiVax Inc - Opportunities
EpiVax Inc - Threats
EpiVax Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
EpiVax Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Dec 29, 2020: EpiVax advances 'PANDA' peptide therapeutic immunogenicity screening program
Dec 15, 2020: EpiVax reports record year for immunogenicity screening toolkit (ISPRI)
Oct 22, 2020: FDA awards $1.1M contract to CUBRC and EpiVax for validation of new immunoinformatic tool for prospective immunogenicity assessment of peptide drugs and their impurities
Jun 03, 2020: Intravacc and EpiVax to develop Covid-19 vaccine candidate
Apr 13, 2020: Immunomic partners EpiVax and PharmaJet on Covid-19 vaccine
Apr 04, 2020: EpiVax took $350,000-1 million PPP government loan for COVID-19-struck small businesses, FOIA request shows
Mar 06, 2020: EpiVax partners with UGA researcher on Covid-19 vaccine
Mar 04, 2020: Generex signs contract with EpiVax to develop Ii-Key peptide vaccines to address the coronavirus pandemic

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

EpiVax Inc, Key Facts
EpiVax Inc, Key Employees
EpiVax Inc, Key Employee Biographies
EpiVax Inc, Key Operational Employees
EpiVax Inc, Major Products and Services
EpiVax Inc, History
EpiVax Inc, Subsidiaries
EpiVax Inc, Key Competitors
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
EpiVax Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
EpiVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021